4McConnelI JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinicalprogression of benign prostatic hyperplasia[J]. N Engl JMed,2003 349(25):2387-2398.
5Souverein PC, Erkens JA, Dela Rosette, et al. Drug treatment of benign prostatic hyperpiasia and hospital admission for BPH-related surgery[J]. Eur Urol,2003,43(5) ,528-534.
2McConnell JD, Roehrborn CG, Bautista OM, et al. The long- term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia [J].N Engl J Med, 2003, 349(25) :2387-2398.
3Russell DW, Wilson JD. Steroid 5 alpha-reductase:two genes/two enzymes [J]. Annu Rev Biochem, 1994, 63:25-61.
4Chen W, Zouboulis CC, Fritsch M, et al. Evidence of heterogeneity and quantitative differences of the type 1 5alpha-reductase expression in cultured human skin cells-evidence of its presence in melanocytes [J]. J Invest Dermatol, 1998, 110(1):84-89.
5Yokoi H, Tsuruo Y, Miyamoto T, et al. Steroid 5 alpha-reductase type 1 immunolocalized in the adrenal gland of normal, gonadectomized, and sex hormone-supplemented rats [J]. Histochem Cell Biol, 1998, 109(2):127-134.
6PC Walsh, AB Reyik. Treatment of BPH [J]. Campbell Urology, 1998, 7:1337-1378.
7Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group [J]. Urology, 1999, 53(4) :690-695.
8Sun ZY, Wu HY, Wang MY, et al. The mechanism of epristeride against benign prostatic hyperplasia [J]. Eur J Pharmacol, 1999, 371(2-3) :227-233.
9Wu SF, Sun HZ, Qi XD, et al. Effect of epristeride on the expression of IGF-1 and TGF-beta receptors in androgen-induced castrated rat prostate [J]. Exp Biol Med (Maywood), 2001,226(10) :954-960.
10Robinson-EJ, Collins-AT. Effects of a new 5 alpha reductase inhibitor (epristeride) on human prostate cell cultures [J]. Prostate, 1997, 32(4) :259-265.
